abs256.txt	in	this	paper		we	develop	a	general	bayesian	clinical	trial	design	methodology	tailored	for	time-to-event	trials	with	a	cured	fraction	in	scenarios	where	apreviously	completed	clinical	trial	is	available	to	inform	the	design	andanalysis	of	the	new	trial		our	methodology	provides	a	conceptually	appealing	andcomputationally	feasible	framework	that	allows	one	to	construct	a	fixed	maximally	informative	prior	a	priori	while	simultaneously	identifying	the	minimumsample	size	required	for	the	new	trial	so	that	the	design	has	high	power	andreasonable	type	i	error	control	from	a	bayesian	perspective		this	strategy	isparticularly	well	suited	for	scenarios	where	adaptive	borrowing	approaches	arenot	practical	due	to	the	nature	of	the	trial		complexity	of	the	model		or	thesource	of	the	prior	information		control	of	a	bayesian	type	i	error	rate	offers	asensible	balance	between	wanting	to	use	high-quality	information	in	the	designand	analysis	of	future	trials	while	still	controlling	type	i	errors	in	anequitable	way		moreover		sample	size	determination	based	on	our	bayesian	view	ofpower	can	lead	to	a	more	adequately	sized	trial	by	virtue	of	taking	into	accountall	the	uncertainty	in	the	treatment	effect		we	demonstrate	our	methodology	bydesigning	a	cancer	clinical	trial	in	high-risk	melanoma	
